Person:
ÖZDEMİR, RAMAZAN

Profile Picture
Google ScholarScopusORCIDPublons
Status
Organizational Units
Job Title
First Name
RAMAZAN
Last Name
ÖZDEMİR
Name
Email Address
Birth Date

Filters

2020 - 202416
Reset filters

Settings

End date: 2024 × Start date: 2020 × Item Type: Publication ×

Search Results

Now showing 1 - 10 of 16
  • No Thumbnail Available
    PublicationMetadata only
    Prognostic impact of chronic obstructive pulmonary disease in octogenarians undergoing transcatheter aortic valve replacement
    (2020-12-06T00:00:00Z) KARAÇÖP, ERDEM; ENHOŞ, ASİM; BAKSHALİYEV, NİJAD; ÖZDEMİR, RAMAZAN; KARAÇÖP, ERDEM; ENHOŞ, ASIM; ÖZDEMİR, RAMAZAN
  • No Thumbnail Available
    PublicationMetadata only
    The analysis of the relationship between low vitamin D levels and cardiovascular diseases: hypertension, cardiac hypertrophy, atrial fibrillation, stroke
    (2020-12-06T00:00:00Z) UÇAR, OĞUZHAN; BACAKSIZ, AHMET; KULA, ASLI YAMAN; ÖZDEMİR, RAMAZAN; HOCAOĞLU, NİSA; ENHOŞ, ASİM; KARAÇÖP, ERDEM; BACAKSIZ, AHMET; ÖZDEMİR, RAMAZAN; ENHOŞ, ASIM; KARAÇÖP, ERDEM
  • Thumbnail Image
    PublicationOpen Access
    P Wave Duration/P Wave Voltage Ratio Plays a Promising Role in the Prediction of Atrial Fibrillation: A New Player in the Game
    (2021-05-01T00:00:00Z) KARAÇÖP, ERDEM; ENHOŞ, Asim; BAKHSALIYEV, NIJAD; ÖZDEMİR, Ramazan; KARAÇÖP, ERDEM; ENHOŞ, ASIM; BAKHSALIYEV, NIJAD; ÖZDEMİR, RAMAZAN
    Background. Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice. Identification of patients at risk for developing AF and the opportunity for early targeted intervention might have a significant impact on morbidity and mortality. Prolonged P wave duration and decreased P wave voltage have been shown to be independent predictors of AF. The present study aimed to investigate the role of P wave duration/P wave voltage in predicting new-onset AF. Methods. We screened a total of 640 consecutive patients who admitted to cardiology outpatient clinic with a complaint of palpitation between 2012 and 2014. 24-h Holter monitoring, echocardiography, and electrocardiography (ECG) recordings were reviewed to identify new-onset AF. Patients were assigned into two groups based on presence (n = 150) and absence (n = 490) of new-onset AF. Previous ECGs with sinus rhythm were analyzed. P wave duration was measured in inferior leads, and P wave voltage was measured in lead one. P wave duration/P wave voltage was also calculated for each patient. Results. One hundred fifty subjects (23.4%) had new-onset AF among 640 patients. P wave duration (123.27 +/- 12.87 vs. 119.33 +/- 17.39 ms, p=0.024) and P wave duration/P wave voltage (1284.70 +/- 508.03 vs. 924.14 +/- 462.06 ms/mV, p<0.001) were higher, and P wave voltage (0.12 +/- 0.04 vs. 0.13 +/- 0.04 mV, p<0.001) was significantly lower in the new-onset AF group compared with non-AFs. P wave duration/P wave voltage, with a cut off of 854.5 ms/mV, had 83.3% sensitivity and 62.0% specificity in a receiver operating characteristic curve (AUC 0.728, 95% CI 0.687-0.769; p<0.001). Their negative and positive predictive values were 78.7% and 68.6%, respectively. In a univariate regression analysis, age, smoking, C-reactive protein, brain natriuretic peptide, left atrial diameter, left atrial volume index, P wave duration, P wave voltage, and P wave duration/P wave voltage were significantly associated with the development of new-onset AF. Moreover, smoking (OR 4.008, 95% CI 1.707-9.409; p=0.001), left atrial volume index (OR 7.108, 95% CI 4.400-11.483; p<0.001), and P wave duration/P wave voltage (OR 1.002, 95% CI 1.000-1.003; p=0.044) were found to be significant independent predictors of new-onset AF in a multivariate analysis, after adjusting for other risk parameters. Conclusion. The P wave duration/P wave voltage ratio is a practical, easy-to-use, cheap, and reliable electrocardiographic parameter, which can play a promising role for both in predicting and elucidating a mechanism of new-onset AF.
  • No Thumbnail Available
    PublicationMetadata only
    Multiple Anterior Mitral Valve Perforation After Deep Transfemoral Aortic Valve Implantation
    (2022-01-01) FOTBOLCU H.; ÖZDEMİR R.; FOTBOLCU, HAKAN; ÖZDEMİR, RAMAZAN
    Transcatheter aortic valve implantation (TAVI) is an alternative for high-risk aortic valve replacement. There are limited data related to the late complications of TAVI. Deep aortic prosthetic valve implantation can cause direct erosive perforation of anterior mitral leaflet or erosive endothelial lesion which predisposes the tissue to infective endocarditis. Our report emphasizes anterior mitral leaflet perforation after TAVI, which may be seen especially in patients exposed to sepsis.
  • Thumbnail Image
    PublicationOpen Access
    THE IMPACT OF ATRIAL FLOW REGULATOR IMPLANTATION ON HEMODYNAMIC PARAMETERS IN PATIENTS WITH HEART FAILURE
    (2021-01-01T00:00:00Z) BAKHSALIYEV, NIJAD; ÖZDEMİR, Ramazan; BAKHSALIYEV, NIJAD; ÖZDEMİR, RAMAZAN
    Background Left atrial decompression has emerged a new option to treat patients with heart failure and dyspnea at rest or during exercise. Here we report the impact of atrial flow regulator (AFR) implantation on hemodynamic parameters in patients at our center with heart failure and with reduced (HFrEF) or with preserved left ventricular ejection fraction (HFpEF).
  • No Thumbnail Available
    PublicationMetadata only
    Impact of atrial flow regulator (AFR) implantation on 12-month mortality in heart failure Insights from a single site in the PRELIEVE study
    (2021-08-01T00:00:00Z) BAKHSALIYEV, NIJAD; ÇELİKKALE, İLKE; ENHOŞ, Asim; KARAÇÖP, ERDEM; ULUGANYAN, Mahmut; ÖZDEMİR, Ramazan; BAKHSALIYEV, NIJAD; ÇELİKKALE, İLKE; ENHOŞ, ASIM; KARAÇÖP, ERDEM; ULUGANYAN, MAHMUT; ÖZDEMİR, RAMAZAN
    Background Implantation of the atrial flow regulator (AFR) to create an interatrial left-to-right shunt has been shown to be safe and feasible to reduce intracardiac filling pressures in patients with heart failure (HF). Objectives We aimed to assess the effect of AFR implantation on 12-month mortality and hospitalization rates in patients with reduced (HFrEF) or preserved HF (HFpEF). Methods One-year follow-up data from 34 subjects enrolled at a single PRELIEVE center were analyzed. The 12-month predicted mortality was calculated using the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score. Patients were divided into two groups, according to their history of hospitalizations for HF. Results Study data of 34 patients (HFrEF: 24 [70.6%]; HFpEF: 10 [29.4%]) were assessed. Median follow-up duration was 355 days. In total, 14 (41.2%) patients were hospitalized during the follow-up period and 6 (17.6%) of these patients were hospitalization for HF (HHF). A total of 24 hospitalizations occurred in this period and 8 (33%) hospitalizations were for HHF. The median baseline MAGGIC score was 23 and the median predicted mortality was 13.4/100 patient years. Observed mortality was 3.1/100 patient years. The observed survival (97%) was 10.3% (95% confidence interval 3.6-17.5%, p = 0.004) better than the predicted survival (86.6%). Conclusion Our results suggest that AFR implantation has favorable effects on mortality in patients with heart failure, regardless of ejection fraction. Furthermore, compared to baseline, left ventricular filling pressure (assessed by echocardiography) decreased significantly without right side volume overload at the 1-year follow-up.
  • No Thumbnail Available
    PublicationMetadata only
    P wave duration / P wave voltage ratio plays a strong role for prediction of atrial fibrillation: A new player in the game
    (2020-12-06T00:00:00Z) KARAÇÖP, ERDEM; ENHOŞ, ASİM; BAKSHALİYEV, NİJAD; ÖZDEMİR, RAMAZAN; KARAÇÖP, ERDEM; ENHOŞ, ASIM; ÖZDEMİR, RAMAZAN
  • No Thumbnail Available
    PublicationMetadata only
    covid-19 pandemisinde hastalık/hastane yönetimi
    (2021-11-01T00:00:00Z) Uluganyan, Mahmut; Özdemir, Ramazan; ULUGANYAN, MAHMUT; ÖZDEMİR, RAMAZAN
  • Thumbnail Image
    PublicationOpen Access
    One-year results of the first-in-man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study
    (2021-03-01T00:00:00Z) Paitazoglou, Christina; Bergmann, Martin W.; ÖZDEMİR, Ramazan; Pfister, Roman; Bartunek, Jozef; KILIÇ, TEOMAN; Lauten, Alexander; Schmeisser, Alexander; ZOGHİ, MEHDİ; Anker, Stefan D.; Sievert, Horst; Mahfoud, Felix; ÖZDEMİR, RAMAZAN
    Aims Attenuating exercise-induced elevated left atrial pressure with an atrial shunt device is under clinical investigation for treatment of symptomatic heart failure (HF). Methods and results PRELIEVE was a prospective, non-randomised, multicentre, first-in-man study in symptomatic HF patients with reduced (HFrEF) or preserved (HFpEF) ejection fraction and pulmonary capillary wedge pressure (PCWP) >= 15 mmHg at rest or >= 25 mmHg during exercise. Here, we provide follow-up data up to 1 year after implantation of the Atrial Flow Regulator (AFR) device. The AFR was successfully implanted in 53 patients (HFrEF n = 24 and HFpEF n = 29). Two patients were not enrolled due to an unsuccessful transseptal puncture. There was one device embolisation into the left atrium, which required surgical removal. One patient experienced a serious procedure-related adverse event (post-procedural bleeding and syncope). All patients with sufficient echocardiography readout confirmed device patency with left-right shunt both at 3 (n = 47/51, 92%) and 12 (n = 45/49, 92%) months. At 3 months, rest PCWP decreased by 5 (-12, 0) mmHg (P = 0.0003, median Q1, Q3). No patient developed a stroke, worsening of right heart function or significant increase of pulmonary artery pressure. Six (6/53, 11%) patients were hospitalised for worsening of HF and three (3/53, 6%) patients died. We observed improvements in New York Heart Association functional class, 6-min walking distance and quality of life (Kansas City Cardiomyopathy Questionnaire) in certain patients. Conclusions Implantation of the AFR device in HF patients was feasible. No shunt occlusion, stroke or new right HF was observed during the 1-year follow-up, with clinical improvements in certain patients.
  • Thumbnail Image
    PublicationOpen Access
    The impact of hydroxychloroquine-azithromycin combination on Tpeak-to-end and Tpeak-to-end/QT ratio during a short treatment course
    (2021-05-01T00:00:00Z) BAKHSALIYEV, NIJAD; ÖZDEMİR, Ramazan; BAKHSALIYEV, NIJAD; ÖZDEMİR, RAMAZAN
    Background: Since there was no proven treatment of coronavirus disease 2019 (COVID-19), hydroxychloroquine-azithromycin (HCQ-AZM) combination is being used in different countries as a treatment option. Many controversies exist related to the safety and effectiveness of this combination, and questions about how HCQ-AZM combination affects the ventricular repolarization are still unknown. Objective: The aim of the study was to show whether the hydroxychloroquine-azithromycin (HCQ-AZM) combination prolonged Tpeak-to-end (TpTe) duration and TpTe/QT interval ratio or not. Methods: One hundred and twenty-six consequent COVID-19(+) patients meeting the study criteria were enrolled in this study. Baseline ECGs were obtained immediately after hospitalization and before commencing the HCQ-AZM combination. On-treatment ECG was obtained 24-48 hr after the loading dose of HCQ/AZM. ECG parameters including PR interval, QRS duration, QT interval, QTc interval, TpTe duration, and TpTe/QT interval ratio were assessed. Demographic and laboratory findings were collected from an electronic recording system. Results: ECGs of 126 COVID-19(+) patients who received HCQ-AZM combination were assessed. Mean baseline QTc (by Fridericia formula), TpTe, and TpTe/QT ratio were 420.0 ± 26.5 ms, 82.43 ± 9.77 ms, and 0.22 ± 0.02, respectively. On-treatment QTc, TpTe and TpTe/QT ratio were 425.7 ± 27.18 ms, 85.17 ± 11.17 ms, and 0.22 ± 0.03, respectively. No statistically significant acute impacts of HCQ-AZM combination on TpTe duration and TpTe/QT interval ratio were observed compared with baseline values. No ventricular tachycardia/fibrillation and the significant conduction delays were seen during in-hospital follow-up. Conclusion: HCQ-AZM combination increased TpTe duration. However, no significant impact on TpTe/QT interval ratio was observed.